**Article**

**Combined in silico, ex vivo, and in vivo assessment of L-17, a thiadiazine derivative with putative neuroprotective and antidepressant-like effects**

Alexey Sarapultsev*1, Pavel Vassiliev2, Daniil Grinchii3, Alexander Kiss4, Mojmir Mach5, Jana Osacka4, Alexandra Balloova5, Ruslan Paliokha5, Andrey Kochetkov6, Larisa Sidorova7, Petr Sarapultsev1, Oleg Chupakhin6,7, Maxim Rantsev8, Alexander Spasov3, Eliyahu Dremencov3,4*

1 Institute of Immunology and Physiology of the Ural Branch of RAS, Pervomayskaya 106, Ekaterinburg 620049, Russia
2 Department of Pharmacology and Bioinformatics, Volgograd State Medical University, Pavshikh Bortsov Square 1, Volgograd 400131, Russia
3 Institute of Molecular Physiology and Genetics, Center of Biosciences, Slovak Academy of Sciences, Dúbravská cesta 9, Bratislava 840 05, Slovakia
4 Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Dúbravská cesta 9, Bratislava 840 05, Slovakia
5 Institute of Experimental Pharmacology and Toxicology, Center of Experimental Medicine, Slovak Academy of Sciences, Dúbravská cesta 9, Bratislava 840 04, Slovakia
6 Ural Federal University named after the First President of Russia B. N. Yeltsin, 19 Mira Street, Ekaterinburg 620002, Russia
7 The IJ Postovsky Institute of Organic Synthesis of the Ural Branch of RAS, Akademicheskaya/S. Kovalevskoi, 22/20, Ekaterinburg 620990, Russia
8 Ural State Medical University, Repina 3, Ekaterinburg 620014, Russian Federation

* Correspondence: a.sarapultsev@gmail.com; eliyahu.dremencov@savba.sk

**Abstract:** L-17 is a thiadiazine derivative with putative anti-inflammatory, neuroprotective, and antidepressant-like properties. In this study, we applied combined in silico, ex vivo, and in vivo electrophysiology techniques to reveal the potential mechanism of action of L-17. PASS 10.4 Professional Extended software suggested that L-17 might have pro-cognitive, antidepressant, and antipsychotic effects. Docking energy assessment with AutoDockVina predicted that the binding affinities of L-17 to the serotonin transporter (SERT) and serotonin receptors 3 and 1A (5-HT3 and 5-HT1A) receptors are compatible to the selective serotonin reuptake inhibitor (SSRI) fluoxetine and selective antagonists of 5-HT3 and 5-HT1A receptors, granisetron and WAY100135, respectively. Acute pre-treatment with L-17 robustly increased c-Fos immunoreactivity in the amygdala (central nucleus), suggesting increased neuronal excitability in this brain area after L-17 administration. Acute L-17 also dose-dependently inhibited of 5-HT neurons of the dorsal raphe nucleus (DRN). This inhibition was partially reversed by subsequent administration of WAY100135, suggesting the involvement of extracellular 5-HT. Based on in silico predictions, c-Fos immunohistochemistry, and in vivo electrophysiology, we suggest that L-17 is a potent 5-HT reuptake inhibitor and/or partial 5-HT1A receptor antagonist. Thus, L-17 might be a representative of a new class of antidepressant drugs. Since L-17 also possesses neuro- and cardio-protective properties, it can be useful in post-stroke and post-myocardial infarction (MI) depression. In general, combined in silico predictions and ex vivo neurochemical and in vivo electrophysiological assessment might be a useful strategy for early preclinical assessment of the affectivity and neural mechanism in action of the novel CNS drugs.
Keywords: thiadizines; serotonin transporter (SERT); serotonin receptors 3 and 1A (5-HT3 and 5-HT1A) receptors, docking energy, binding affinity, binding mechanisms, c-Fos immunohistochemistry, electrophysiology in vivo

1. Introduction

L-17 (2-morpholino-5-phenyl-6H-1,3,4-thiadiazine, hydrobromide; Fig. 1) is a thiadiazine derivative, synthesized by cyclocondensation of α-bromoacetophenone with the original morpholine-4-carbothionic acid hydrazide [1]:

![Figure 1. Structural chemical formulas of 2-morpholino-5-phenyl-6H-1,3,4-thiadiazine, hydrobromide (I) (L-17), compared the selective serotonin reuptake inhibitor fluoxetine (II), serotonin-3 (5-HT3) receptor antagonist granisetron (III) and serotonin-1A (5-HT1A) receptor antagonist WAY100135 (IV).](image)

In our previous studies, L-17 we have shown a putative therapeutic effect of myocardial infarction (MI) [2-4] and pancreatitis [5] in animal models. L-17 has also been reported to attenuate the immune system response to the immobilization stress in rats, suggesting an immunostimulatory effect of this compound during the stress coping [4]. Neuroprotective [1] and antidepressant-like [6] effects of L-17 in rats have been demonstrated, as well. In this study, we aimed to investigate the mechanism of the putative beneficial effect of L-17 on the central nervous system (CNS), using a combination of in silico, ex vivo, and in vivo methods [7].

For in silico assessments, we constructed three-dimensional (3D) model of L-17, and examined its interaction with different targets, such as serotonin (5-HT) transporter (SERT) and 5-HT receptors 3 and 1A (5-HT3/5-HT1A), used the calculation of the minimum binding energy. SERT and 5-HT3 were chosen because they play a primary role in the pathophysiology and treatment of CNS disorders.

Immunohistochemical assessment of proto-oncogene Fos across the brain is an ex vivo experimental technique used for the investigation of mechanism of action of novel CNS drugs. The activation of the proto-oncogene Fos, resulting in an increased expression of its protein product c-Fos, is a well-established marker for the neuronal excitability within the specific brain area [8-11]. Increased proto-oncogene Fos expression in the amygdala, indicating increased neural excitability in this brain area, has been observed after administration of various CNS drugs, such as typical [12] and atypical antipsychotics [12-14], tricyclic antidepressants [13], and selective 5-HT reuptake inhibitors
(SSRIs) [13, 15, 16]. The SSRI citalopram-induced increase in c-Fos immunoreactivity has been shown to be potentiated by the selective antagonist of 5-HT_{1A} receptors WAY100638 [17], suggesting a key role of 5-HT system in the modulation of amygdaloid excitability by CNS drugs. With regards to the prefrontal cortex (PFC), some SSRIs, such as fluvoxamine [16], and some atypical antipsychotics, such as olanzapine [18, 19], increased local c-Fos immunoreactivity. On the other hand, 5-HT depletion led to an increased c-Fos immunoreactivity in the PFC and hippocampus [20], suggesting that extracellular 5-HT suppresses neural excitability and Fos proto-oncogene expression in these brain areas.

Finally, we used single-unit extracellular electrophysiology in vivo to examine the effect of L-17 on the excitability of 5-HT neurons in the rat dorsal raphe nucleus (DRN). Multiple antidepressant drugs, such as tricyclic antidepressants, SSRIs, dual 5-HT/norepinephrine, and triple 5-HT/norepinephrine/dopamine reuptake inhibitors, pyridoindoles (experimental drugs with putative triple reuptake inhibition property), and some atypical antipsychotics, except potent acute inhibitory effect on the excitability of 5-HT neurons of the DRN. This inhibition is usually reversed by the selective 5-HT_{1A} receptors antagonist, suggesting the involvement of the extracellular 5-HT. The assessment of the effect of an experimental CNS drug on the excitability of 5-HT neurons is a key marker for the preclinical assessment of its efficacy.

2. Results

2.1. In silico predictions

The following pharmacological activities were predicted for L-17 by the PASS 10.4 Professional Extended [21]: cognition disorders treatment (Pa = 0.489, Pa/Pi = 27.17), phobic disorders treatment (Pa = 0.703, Pa/Pi = 9.37), psychotropic (Pa = 0.258, P /Pi = 1.74), immunostimulant (Pa = 0.191, Pa/Pi = 1.39), and antidepressant (Pa = 0.162, Pa/Pi = 1.14) one. According to joint predictive evaluations in PASS and experimental data [1, 6], the most likely targeted activities corresponding to the serotoninergic effects of compound L-17 were suggested: 5-HT$_3$ antagonism (Pa = 0.139, Pa/Pi = 1.17), 5-HT release inhibition (Pa = 0.225, Pa/Pi = 1.01), and 5-HT reuptake blockade (Pa = 0.470, Pa/Pi = 6.35). While L-17 compound manifests itself as an atypical mild antipsychotic and antidepressant [1], for the subsequent analysis of its multitarget mechanism of action the serotonin transporter (SERT), the serotonin receptor types 3 (5-HT$_3$) and 1A (5-HT$_{1A}$) were chosen as target proteins (Tab 1).

| Molecule | $\Delta E$, kcal/mol | pK | RA | $\Delta E$, kcal/mol | pK | RA | $\Delta E$, kcal/mol | pK | RA |
|----------|----------------------|----|----|----------------------|----|----|----------------------|----|----|
| L-17     | -8.1                 | 5.90 | 0.87 | -6.6                 | 4.81 | 0.94 | -7.9                 | 5.78 | 0.85 |
| Fluoxetine | -9.3                 | 6.78 | -     | -6.7                 | 5.10 | -     | -6.7                 | 6.78 | -   |
| Granisetron | -                  | -   | -     | -6.7                 | 5.10 | -     | -6.7                 | 6.78 | -   |
| WAY100135 | -                   | -   | -     | -6.7                 | 5.10 | -     | -6.7                 | 6.78 | -   |

Table 1. Docking energy ($\Delta E$), binding affinity (pK), and relevant affinity (RA) of L-17 to the SERT and 5-HT$_3$/5-HT$_{1A}$ receptors, compared to the selective SERT, 5-HT$_3$, 5-HT$_{1A}$ ligands: fluoxetine, granisetron, and WAY100135.
Figure 2 illustrates the binding mechanisms of L-17, fluoxetine, granisetron, and WAY100135 with the SERT and 5-HT3 and 5-HT1A receptors, predicted using the LigandScout 4.2.1 software [22].

Figure 2. Binging mechanisms of L-17, fluoxetine, granisetron, and WAY100135 with the SERT and 5-HT3 and 5-HT1A receptors.
Figure 3 illustrates the poses of L-17, fluoxetine, granisetron, and WAY100135 with the binding sites of SERT and 5-HT$_3$ and 5-HT$_{1A}$ receptor:

![Images of L-17, fluoxetine, granisetron, and WAY100135 in their binding sites.](image)

**Figure 3.** Poses of L-17, fluoxetine, granisetron, and WAY100135 with the binding sites of SERT and 5-HT$_3$ and 5-HT$_{1A}$ receptor

The pose of L-17 within the SERT binding site is remarkably close to this of fluoxetine. There is also a partial similarity between L-17 and WAY100134 poses within the binding site of the 5-HT$_{1A}$ receptor. The poses of L-17 and granisetron within the binding site of the 5-HT$_3$ receptor are remarkably different.
2.2. Proto-oncogene Fos expression

Figure 4 illustrates the expression of proto-oncogene Fos in three selected brain areas, including prefrontal cortex (PFC, A-C), hippocampus (D-F), and amygdala (G-I) of vehicle- and L-17-pretreated rats:

![Figure 4](image_url)

**Figure 4.** Representative sections illustrating the expression and distribution of c-Fos protein immunolabeled cells in the prefrontal cortex (PFC, A-C), hippocampus (D-F), and the central nucleus of the amygdala (G-I) in vehicle- and L-17-pretreated rats. *p<0.05 and p<0.001, two-tailed Student’s t-test.

Pre-treatment with L-17 decreased c-Fos immunoreactivity in the hippocampus and increased it in the amygdala. The expression of c-Fos in the PFC was not statistically different between the groups. Summary quantitative assessments were done from four vehicle- and four L-17-administered rats.

2.3. In vivo electrophysiology

The mean basal firing activity was 3.46±0.83 Hz. L-17 (0.1–12 mg/kg, i.v.) significantly and dose-dependently (F_{8,53}=4.84, p<0.001, ANOVA for repeated measured) inhibited the firing activity of 5-HT neurons, reaching the maximal 90%-inhibition at 12 mg/kg. WAY100135 partially reversed the L-17-induced inhibition of 5-HT neurons (Fig 4):
Figure 4: L-17 significantly and dose-dependently inhibited the firing activity of 5-HT neurons. A: representative recording from a 5-HT neuron during L-17 (12 mg/kg) and WAY100135 (0.3 mg/kg) administration. B: Summary effect of L-17 (0.1-12 mg/kg) and WAY100135 (0.3 mg/kg) on the spontaneous firing activity of 5-HT neurons of the DRN (data from 8 neurons from 7 rats).

3. Discussion

In this study, we performed a complex in silico assessment of pharmacotherapeutic properties of L-17, as well as in vivo electrophysiological assessment of the effect of this compound on the firing activity of 5-HT neurons in the rat DRN. PASS 10.4 Professional Extended [21] software predicted antidepressant-like properties of L-17. This prediction is consistent with the previously reported antidepressant-like effect of L-17 in rats [6]. PASS 10.4 Professional Extended had also predicted that the antidepressant-like effect of L-17 can be explained, at least in part, via its 5-HT reuptake inhibition property.

AutoDockVina 1.1.2 [23] docking energy assessment predicted that L-17 has an affinity to the SERT comparable with fluoxetine, 5-HT3 binding affinity similar to granisetron, and 5-HT1A binding affinity comparable to WAY100135. The prediction of the molecular interactions between L-17 and the binding sites of SERT and 5-HT3 and 5-HT1A receptors with LigandScout 4.2.1 software [22] revealed that the mechanisms of L-17 binding to the SERT and 5-HT1A receptor are similar to fluoxetine and WAY100135, respectively. On the other hand, L-17 binding to 5-HT3 receptors is completely different from that of granisetron. Consistently, the topographic poses of L-17 within SERT and 5-HT1A receptor binding sites are remarkably similar to those of fluoxetine and WAY100135, respectively. Thus, the morpholine cycle nitrogen atom of L-17 is engaged in a π-π exchange with PHE269 of SERT. If protonated, this nitrogen forms a region of undirected electrostatic interaction. Two more structural elements of L-17 participate in five nonspecific hybrid interactions with TYR23, ALA97, ILE100, ALA101, TYR104 of the SERT. Fluoxetine is being banded to the SERT via the electrostatic interaction of protonated NH2 group. Three additional groups of L-17 form five hydrogen bonds with TYR23, ALA24, ASP26, SER367x. Three more structural elements participate in six nonspecific hybrid interactions with ILE100, ALA101, TYR104, PHE269, LEU371, VAL429. L-17 might bind to the 5-HT3 receptor by stacking with PHE97. Two structural elements of L-17 participate in four nonspecific hybrid interactions with LEU93, PHE97, VAL100, LEU123. No stacking is observed in granisetron binding to a 5-HT3 receptor. Fixation is exerted by three nonspecific hydrophobic interactions with ILE38, TRP57, TYR120. The morpholine cycle oxygen atom of L-17 forms a hydrogen bond with TYR366 of the binding site of the 5-HT3 receptor. Two structural
elements of L-17 form three nonspecific hydrophobic links with TRP78, PHE88, and ILE89 of the binding site of 5-HT1A receptor. The protonated nitrogen atom of the morpholine cycle of WAY100135 exerts electrostatic interaction with TYR366. Two WAY100135 molecule fragments participate in three nonspecific hydrophobic interactions with ALA69, TYR72, TRP78, ILE89, VAL93, ILE165, ALA179, PHE338, LEU357 of the binding site of the 5-HT3 receptor.

It has been demonstrated that the pre-treatment with L-17 robustly increased c-Fos immunoreactivity in the amygdala. Amygdala is a fundamental structure in the emotional responses, including fear and anxiety [24]. Thus, it is possible that the modulation of amygdaloid neural excitability is involved in the therapeutic response to antidepressant, anxiolytic, and mood stabilizing medicines. It has indeed been reported that various CNS drugs, such typical [12] and atypical antipsychotics [12-14], tricyclic antidepressants [13], and selective 5-HT reuptake inhibitors (SSRIs) [13, 15, 16], increased c-Fos immunoreactivity in the amygdala, indicating an increased neural excitability in this brain area. In our previous studies, we have found that pyridoindole derivate SMe1EC2M3, a molecule with putative 5-HT reuptake inhibition properties and antidepressant-like behavioral effect [7], stimulated amygdaloid c-Fos immunoreactivity, as well [11]. The fact that SSRI-induced amygdaloid c-Fos immunoreactivity was potentiated by an antagonist of 5-HT1A autoreceptors indicated that 5-HT system is involved in the modulation of amygdaloid neural excitability by antidepressant drugs. Thus, it can be summarized that the induction of amygdaloid c-Fos immunoreactivity is an important marker for the putative mood stabilizing and antidepressant-like effect, and the fact that L-17 stimulated proto-oncogene Fos expression in the amygdala brings an additional support to the hypothesized beneficial effects of this molecule as a future CNS drug.

With regards to proto-oncogene Fos expression in other brain areas, we found that acute administration of L-17 significantly decreased c-Fos immunoreactivity in the hippocampus and tended to decrease it also in the PFC. It has been previously reported that 5-HT depletion led to an increased c-Fos expression in these brain areas [20]. Thus, it is possible that the L-17-induced decrease in forebrain c-Fos immunoreactivity might be explained by the ability of this drug to elevate extracellular 5-HT concentrations. Further studies should be, however, performed to test this hypothesis.

We found that acute intravenous administration of L-17 significantly and dose-dependently inhibited the firing activity of 5-HT neurons of the DRN. Similar inhibitory effects on 5-HT neuronal firing activity has been observed with other SSRIs, such as citalopram [25], escitalopram [25, 26], Wf-516 [27] or paroxetine [28]. Similar to that observed in other SSRIs, the L-17-induced inhibition of 5-HT neuronal firing activity was reversed by WAY100135. It is likely that L-17 is acting as a potent SERT blocker. Inhibition of the SERT by acute L-17 leads to an increase in the extracellular 5-HT levels, activation of 5-HT1A autoreceptors, and reduction of firing activity of 5-HT neurons. The subsequent blockade of 5-HT1A autoreceptors reverses the inhibition of 5-HT neurons.

On the other hand, unlike escitalopram-induced suppression of 5-HT neuronal firing activity, which was completely reversed by 0.1 mg/kg of WAY100135 [25, 26], the L-17-induced inhibition of 5-HT neurons was reversed by WAY100135 only partially, even though WAY100135 was administered at 0.3 mg/kg. Thus, it is possible that L-17 interacts with a molecular target(s) other than SERTs. One of these targets predicted by in silico tests is 5-HT receptor. It is possible that L-17 acts, in addition to its function as a SERT blocker, as a partial agonist of 5-HT1A receptors. The competition
between L-17 and WAY100135 on 5-HT1A receptors putatively prevents complete WAY100135-mediated recovery of firing activity of 5-HT neurons. Another possibility might be, however, a direct interaction of L-17 with α1-adrenoceptors [29].

Summarizing, the antidepressant-like properties of L-17, reported in previous studies, can be explained, at least in part, by the ability of this compound to modulate the central 5-HT neurotransmission. We cannot, however, exclude the interaction of L-17 with receptors modulation the excitability of 5-HT neurons, such as 5-HT1A, 5-HT3 and/or α1/2-adrenergic receptors. It is also possible that L-17 directly interacts with other neurotransmitter systems, such as norepinephrinergic, dopaminergic, and/or histaminergic ones. The L-17-induced modulation of 5-HT transmission is likely to be mediated, at least in part, via the inhibition of 5-HT reuptake and partial antagonism to 5-HT1A receptors. L-17-induced increase in 5-HT ton? putatively results in increased neuronal excitability in the amygdala and decreased neuronal firing activity in the hippocampus. These L-17-induced changes in neural excitability across the brain might be involved in the neuroprotective and antidepressant-like behavioral effects of this compound, reported in previous studies. This previously reported antidepressant-like properties of L-17 and its modulatory effect on 5-HT neurons of the DRN and on the neural excitability in the amygdala and the hippocampus, reported in this study, suggest that L-17 might be an effective antidepressant drug. Since L-17 also possesses neuro- and cardio-protective properties, it could be useful in affective illness developing due to the general medical condition, such as post-stroke and post-MI depression. It should be also stated that the combined in silico (computerized molecular binding mechanisms prediction), ex vivo (assessment of the neuronal excitability using c-Fos immunoreactivity measurement) and in vivo (direct assessment of excitability of monoamine-secreting neurons) investigation might be a useful strategy for early preclinical assessment of the affectivity and neural mechanism of action in the novel CNS drugs.

4. Materials and Methods
4.1. In silico predictions

Using the PASS 10.4 Professional Extended software [21], the presence (Pa) or absence (Pi) probability of 480 systemic types of pharmacotherapeutic activity was calculated. Promising activities were those with Pa ≥0.1 and Pa/Pi ≥1.0.

Further, for a comparative evaluation of the L-17 compound’s affinity to the selected biotargets, the docking of the compound to the specific binding sites of these proteins was performed. Five experimental X-ray 3D models of SERT were obtained from Protein Data Bank in Europe[30]. Among these five models, the longest one (PDB code 5I6X), with the maximum resolution including an inhibitor, was chosen to allow the unambiguous determination of the binding site position [31]. The experimental 3D models for 5-HT3 and 5-HT1A receptors were not available in Protein Data Bank in Europe, therefore a search for the best theoretical 3D models from the Database of Comparative Protein Structure Models [32]was conducted. Among the available models, the longest ones, with the highest statistical significance, were selected for 5-HT3 [33] and 5-HT1A [34] receptors.

The 3D models of L-17 and reference molecules were constructed using the molecular mechanics’ methods in the MarvinSketch15.6.15 software [35], followed by optimization with the semi-empirical quantum chemical method PM7 in the MOPAC2016 software [36]. The docking was performed using AutoDockVina 1.1.2 [23], five times for each compound into each target and then
the spectrum of energies were used to determine the minimum binding energies. To reveal the mechanisms of serotoninergic action of the compound L-17, an analysis of its affinity spectrum in comparison with the affinity spectra of reference compounds was performed. The primary information about reference compounds for target proteins was obtained from the UniProtKB base [37]. For each reference compound found in the UniProtKB, the mechanism of its action was clarified using the DrugBank [38]. In the case of the information in UniProtKB and DrugBank datasets was not sufficient, the search for references was performed in the database of pharmacologically relevant proteins and their ligands IUPHAR [39]. The SSRI fluoxetine and the selective antagonists of 5-HT3 (granisetron) and 5-HT1A (WAY100135) receptors were used as reference molecules. Using the obtained energy spectra of $\Delta E$, the $pK$ values were calculated using the formula:

$$pK = -\log e^{-\Delta E/RT},$$

where $R$ is a universal gas constant (8.314 J mol$^{-1}$ K$^{-1}$) and $T$ is a temperature, set as 300 K. The molecular binding mechanism of L-17, granisetron, and WAT100135 with SERT and with 5-HT3 and 5-HT1A receptors was furtherly evaluated using the LigandScout 4.2.1 software [22]. The data on binding sites were found in the available literature. For SERT, the key amino acids of the binding site were Gly94, Ala96, Val97, Asn101, Ser336, Asn368, Leu434, Asp437, Ser438 [31]. For 5-HT3 receptor, the key amino acids of the binding site were Tyr229, Phe221, Asn123, Trp85, Trp178, Tyr148, Arg87, Gln146, Tyr138 [33]. For 5HT1A receptor, the key amino acids of the binding site were Tyr56, Gln57, Asp76, Val77, Ser159, Thr339, Gly342, Ala343, Ile345, Asn346 [34].

4.2 Assessment of c-Fos immunoreactivity

For the assessment of the proto-oncogene c-Fos expression, rats were pre-treated with L-17 (60 mg/kg, intraperitoneally, i.p.) twenty-four and one hour before immunoreactivity measurements. C-Fos expression was analyzed, as we have reported previously [11, 40]. The rats were anesthetized by a combined treatment of zoletil (30 mg/kg, Virbac, Carros, France) and xylarien (15 mg/kg, Riemser Germany) in the volumes of 0.1 ml and 0.24 ml/300 g b.w., respectively. Then, they were perfused transcardially with 50 ml of cold isotonic saline containing 150 µl of heparin (5000 IU/ml, Zentiva, Slovakia) followed by 200 ml of fixative containing 4% paraformaldehyde (Sigma-Aldrich, Germany) in 0.1 M phosphate buffer (PB, pH 7.4). Immediately after perfusion, the brains were removed from the skulls, postfixed in a fresh fixative overnight, washed in 0.1 M PB at 4 °C overnight, and infiltrated with 30% sucrose (Slavus, Slovakia) at 4 °C for 48 h. Coronal sections of 35-µm thickness were alternatively cut over the whole brain in a cryocut (Hyrax C-50). The sections were repeatedly washed in 0.1 M PB and pretreated with 0.3% H$_2$O$_2$ (Sigma-Aldrich, Germany) in 0.1 M PB for 10 min at room temperature (RT). Thereafter, the sections were rinsed 3 × 10 min in 0.1 M PB and exposed to rabbit anti-Fos polyclonal antibody (1:2000) in 0.1 M PB containing 4% normal goat serum (Gibco, Grand Island, NY, USA), 0.5% Triton X-100 (Sigma-Aldrich, Germany), and 0.1% sodium azide (Sigma-Aldrich, Germany) for 48 h at RT. After several rinsing in PB, the sections were incubated with biotinylated goat anti-rabbit IgG (1:500, BA-9200, VectorStain Elite ABC Kit, Vector Lab, Burlingame, CA, USA) in PB for 90 min at RT. Next, the PB rinsing was followed by incubation with the avidin–biotin-peroxidase complex (1:250) for 90 min at RT. After several washings in 0.05 M sodium acetate buffer (SAB, pH 6.0), c-Fos-antigenic sites were visualized by 3,3'-diaminobenzidine tetrahydrochloride (0.0625% DAB) enhanced with 2.5% nickel chloride (Sigma-Aldrich, Germany), in
SAB containing 0.0006% H₂O₂. Developing time was 6–8 min. The heavy metal intensification of DAB yielded to black staining of c-Fos-labeled nuclei.

The topographic mapping of the c-Fos protein immunolabeled cells was performed in three brain areas (PFC, hippocampus, and central nucleus of the amygdala) identified based on the rat brain atlas [11, 41]. The individual structures investigated were captured unilaterally from 6-10 representative sections using an Axio-Imager A1 light microscope (Carl Zeiss, Jena) coupled to a video camera and monitor. Since the staining of each individual Fos-immunoreactive cell varied from very intense to very light, c-Fos profiles counting was performed on pictures inverted by the Adobe Photoshop 7.0 adjustment INVERT to reach white c-Fos profiles on the black background. The counting of the c-Fos profiles was performed manually in the PC computer by a person blind to the design of the experiment.

4.3 In vivo electrophysiology

In vivo electrophysiological assessment of the excitability of 5-HT neurons of the DRN was performed as previously described [7, 42-44]. Adult male Wistar rats, weighing 300-350 g, were ordered from the Animal Breeding Facility of The Institute of Experimental Pharmacology and Toxicology, Center of Experimental Medicine, Slovak Academy of Sciences in DobráVoda, Slovakia. Rats were anesthetized with chloral hydrate (Lambda Life s.r.o., Bratislava, Slovakia; 0.4 g/kg, intraperitoneally: i.p.) and maintained in a stereotaxic frame (David Kopf Instruments, Tujunga, CA). Rat body temperature was maintained between 36 and 37°C with a heating pad (Gaymor Instruments, Orchard Park, NY, USA). The scalp was opened, and a 3 mm hole was drilled in the skull for insertion of electrodes. Glass-pipettes were pulled with a DMZ-Universal Puller (Zeitz-Instruments GmbH, Martinsried, Germany) to a fine tip approximately 1 μm in diameter and filled with 2M NaCl solution. Electrode impedance ranged from 4 to 6 MΩ. The pipettes were lowered into the DRN (7.8-8.3 mm posterior to bregma and 4.5-7.0 mm ventral to brain surface) [41] by David Kopf Instruments hydraulic micro-positioner. The action potentials generated by 5-HT neurons were recorded using the AD Instruments Extracellular Recording System (Dunedin, New Zealand). The 5-HT neurons were identified by bi- or tri-phasic action potentials with a rising phase of long duration and regular firing rate of 0.5–5.0 Hz [45]. All experimental procedures were approved by the Animal Health and Animal Welfare Division of the State Veterinary and Food Administration of the Slovak Republic (Permit number Ro 3592/15-221) and confirmed to the Directive 2010/63/EU of the European Parliament and of the Council on the Protection of Animals Used for Scientific Purposes.

Author Contributions: Conceptualization, A.Sa., P.V., D.G., A.K., M.M., J.O., O.C., A.Sp. and E.D.; bioinformatics, A.Sa., P.V., and A.K.; synthesis, L.S.; ex vivo experiments, J.O. and A.B.; in vivo experiments, D.G. and R.P.; writing—original draft preparation, A.Sa., P.V., D.G., M.R., and E.D.; writing—review and editing, A.Sa., P.V., D.G., A.K., M.M., M.R., O.C., A.Sp., and E.D.; funding acquisition, A. Sa. and E.D. All authors read the manuscript and agreed to publish it in the present version.

Funding: The work of the authors of this study was supported by the Slovak Research and Development Agency by the Slovak Research and Development Agency (contract APVV-2020-02-02), Scientific Grant Agency of the Ministry of Education of the Slovak Republic, and the Slovak Academy of Sciences (grant VEGA 2/0046/18), Government Contract of the Russian Federation with the Institute of Immunology and Physiology (AAAA-A18-118020690020-1).
**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| 3D           | Three dimensional |
| 5-HT         | 5-hydroxytryptamine (serotonin) |
| ANOVA        | Analysis of variance |
| DRN          | Dorsal raphe nucleus |
| L-17         | 2-morpholino-5-phenyl-6H-1,3,4-thiadiazine, hydrobromide |
| MI           | Myocardial infarction |
| SERT         | Serotonin transporter |
| SSRI         | Selective serotonin reuptake inhibitor |

**References**

1. Sarapultsev, A. P.; Chupakhin, O. N.; Sarapultsev, P. A.; Sidorova, L. P.; Tseitler, T. A., Pharmacologic Evaluation of Antidepressant Activity and Synthesis of 2-Morpholino-5-phenyl-6H-1,3,4-thiadiazine Hydrobromide. *Pharmaceuticals (Basel)* **2016**, *9*, (2).
2. Sarapultsev, P.; Chupakhin, O.; Sarapultsev, A.; Rantsev, M.; Sidorova, L.; Medvedeva, S.; Danilova, I., New insights in to the treatment of myocardial infarction. *Int J Exp Pathol* **2012**, *93*, (1), 18-23.
3. Sarapultsev, A. P.; Chupakhin, O. N.; Sarapultsev, P. A.; Rantsev, M. A.; Medvedeva, S. U.; Sidorova, L. P., Effect of a new class of compounds of the group of substituted 5RI, 6H2-1,3,4-thiadiazine-2amines on the inflammatory and cytokine response in experimental myocardial infarction. *Curr Vasc Pharmacol* **2015**, *13*, (1), 43-53.
4. Sarapultsev, A. P.; Chupakhin, O. N.; Sarapultsev, P. A.; Rantsev, M. A.; Medvedeva, S. U.; Sidorova, L. P.; Abidov, M. T.; Danilova, I. G., Modulation of inflammatory response improves myocardial infarct healing in rats. *Curr Pharm Des* **2014**, *20*, (12), 1980-6.
5. Sarapultsev, A.; Chupakhin, O.; Rantsev, M.; Sarapultsev, P.; Danilova, I.; Medvedeva, S.; Sidorova, L.; Tseitler, T.; Brilliant, S.; Tsellikman, V., Effects of 1,3,4-thiadiazine compound with antidepressant properties in ligation model of acute pancreatitis. *Gen Physiol Biophys* **2018**, *37*, (5), 549-562.
6. Shevelev, O. B.; Illarionova, N. B.; Petrovski, D. V.; Sarapultsev, A. P.; Chupakhin, O. N.; Moshkin, M. P., Effects of a compound from the group of substituted thiaadizaines with hypothermia inducing properties on brain metabolism in rats, a study in vivo and in vitro. *PLoS One* **2017**, *12*, (7), e0180739.
7. Koprdova, R.; Csatllosova, K.; Durisova, B.; Bogi, E.; Majekova, M.; Dremencov, E.; Mach, M., Electrophysiology and Behavioral Assessment of the New Molecule SMe1EC2M3 as a Representative of the Future Class of Triple Reuptake Inhibitors. *Molecules* **2019**, *24*, (23), 14.
8. Bullitt, E., Expression of c-fos-like protein as a marker for neuronal activity following noxious stimulation in the rat. *J Comp Neurol* **1990**, *296*, (4), 517-30.
9. Herdegen, T.; Leah, J. D., Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. *Brain Res Brain Res Rev* **1998**, *28*, (3), 370-490.
10. Slattery, D. A.; Morrow, J. A.; Hudson, A. L.; Hill, D. R.; Nutt, D. J.; Henry, B., Comparison of alterations in c-fos and Egr-1 (zif268) expression throughout the rat brain following acute administration of different classes of antidepressant compounds. *Neuropsychopharmacology* **2005**, *30*, (7), 1278-87.
11. Koprdova, R.; Osacka, J.; Mach, M.; Kiss, A., Acute Impact of Selected Pyridoindole Derivatives on Fos Expression in Different Structures of the Rat Brain. *Cellular and Molecular Neurobiology* **2018**, *38*, (1), 171-180.
12. Cohen, B. M.; Cherkerzian, S.; Ma, J.; Ye, N.; Wager, C.; Lange, N., Cells in midline thalamus, central amygdala, and nucleus accumbens responding specifically to antipsychotic drugs. *Psychopharmacology (Berl)* **2003**, 167, (4), 403-10.

13. Morelli, M.; Pinna, A., Antidepressants and atypical neuroleptics induce Fos-like immunoreactivity in the central extended amygdala. *Ann N Y Acad Sci* **1999**, 877, 703-6.

14. Pinna, A.; Costa, G.; Contu, L.; Morelli, M., Fos expression induced by olanzapine and risperidone in the central extended amygdala. *Eur J Pharmacol* **2019**, 865, 172764.

15. Thomsen, C.; Helboe, L., Regional pattern of binding and c-Fos induction by (R)- and (S)-citalopram in rat brain. *Neuroreport* **2003**, 14, (18), 2411-4.

16. Hayashi, T.; Miyata, M.; Nagata, T.; Izawa, Y.; Kawakami, Y., Intracerebroventricular fluvoxamine administration inhibited pain behavior but increased Fos expression in affective pain pathways. *Pharmacol Biochem Behav* **2009**, 91, (3), 441-6.

17. Sebens, J. B.; Koch, T.; Ter Horst, G. J.; Korf, J., Effect of 5-HT1A receptor-mediated serotonin augmentation on Fos immunoreactivity in rat brain. *Eur J Pharmacol* **2002**, 455, (2-3), 109-15.

18. Robertson, G. S.; Fibiger, H. C., Effects of olanzapine on regional C-Fos expression in rat forebrain. *Neuropsychopharmacology* **1996**, 14, (2), 105-110.

19. Sebens, J. B.; Koch, T.; Ter Horst, G. J.; Korf, J., Olanzapine-induced Fos expression in the rat forebrain; cross-tolerance with haloperidol and clozapine. *Eur J Pharmacol* **1998**, 353, (1), 13-21.

20. Kornum, B. R.; Weikop, P.; Moller, A.; Ronn, L. C.; Knudsen, G. M.; Aznar, S., Serotonin depletion results in a decrease of the neuronal activation caused by rivastigmine in the rat hippocampus. *Brain Res* **2006**, 1073-1074, 262-8.

21. Filimonov, D. A.; Lagunin, A. A.; Gloriozova, T. A.; Rudik, A. V.; Druzhilovskii, D. S.; Pogodin, P. V.; Poroikov, V. V., Prediction of the Biological Activity Spectra of Organic Compounds Using the Pass Online Web Resource. *Chemistry of Heterocyclic Compounds* **2014**, 50, (3), 444-457.

22. Inte:Ligand: Your partner for in silico drug discovery. [http://www.inteligand.com/](http://www.inteligand.com/)

23. Trott, O.; Olson, A. J., AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem* **2010**, 31, (2), 455-61.

24. Amunts, K.; Kedo, O.; Kindler, M.; Pieperhoff, P.; Mohlberg, H.; Shah, N. J.; Habel, U.; Schneider, F.; Zilles, K., Cytoarchitectonic mapping of the human amygdala, hippocampal region and entorhinal cortex: intersubject variability and probability maps. *Anatomy and Embryology* **2005**, 210, (5), 343-352.

25. El Mansari, M.; Sánchez, C.; Chouvet, G.; Renaud, B.; Haddjeri, N., Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. *Neuropsychopharmacology* **2005**, 30, (7), 1269-77.

26. Dremencov, E.; Csatlosova, K.; Durisova, B.; Moravcikova, L.; Lacinova, L.; Jezova, D., Effect of Physical Exercise and Acute Escitalopram on the Excitability of Brain Monoamine Neurons: In Vivo Electrophysiological Study in Rats. *Int J Neuropsychopharmacol* **2017**, 20, (7), 585-592.

27. El Mansari, M.; Blier, P., In vivo electrophysiological assessment of the putative antidepressant Wf-516 in the rat raphe dorsalis, locus coeruleus and hippocampus. *Naunyn-Schmiedebergs Archives of Pharmacology* **2008**, 376, (5), 351-361.

28. Piñeyro, G.; Blier, P.; Dennis, T.; de Montigny, C., Desensitization of the neuronal 5-HT carrier following its long-term blockade. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **1994**, 14, (5 Pt 2), 3036-47.
29. Dremencov, E.; El Mansari, M.; Blier, P., Distinct electrophysiologic effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. *Psychopharmacology (Berl)* 2007, 194, (1), 63-72.

30. PDBe logo Protein Data Bank in Europe. [https://www.ebi.ac.uk/pdbe/](https://www.ebi.ac.uk/pdbe/)

31. Coleman, J. A.; Green, E. M.; Gouaux, E., X-ray structures and mechanism of the human serotonin transporter. *Nature* 2016, 532, (7599), 334-9.

32. ModBase: Database of Comparative Protein Structure Models. [https://modbase.compbio.ucsf.edu/modbase-cgi/index.cgi](https://modbase.compbio.ucsf.edu/modbase-cgi/index.cgi)

33. Price, K. L.; Lillestol, R. K.; Ulens, C.; Lummis, S. C. R., Palonosetron–5-HT3 Receptor Interactions As Shown by a Binding Protein CoCrystal Structure. *ACS Chemical Neuroscience* 2016, 7, (12), 1641-1646.

34. Jaśkowska, J.; Zareba, P.; Śliwa, P.; Pindelska, E.; Satała, G.; Majka, Z., Microwave-Assisted Synthesis of Trazodone and Its Derivatives as New 5-HT(1A) Ligands: Binding and Docking Studies. *Molecules* 2019, 24, (8).

35. MarvinSketch - Create and Design. [https://chemaxon.com/products/marvin](https://chemaxon.com/products/marvin)

36. Stewart Computational Chemistry. [http://openmopac.net/](http://openmopac.net/)

37. UniProtKB. [https://www.uniprot.org/help/uniprotkb](https://www.uniprot.org/help/uniprotkb)

38. DrugBank Online. [https://go.drugbank.com/](https://go.drugbank.com/)

39. IUPHAR/BPS Guide to PHARMACOLOGY. [https://www.guidetopharmacology.org/](https://www.guidetopharmacology.org/)

40. Majercikova, Z.; Weering, H.; Sesukova, S.; Mikkelsen, J. D.; Kiss, A., A new approach of light microscopic immunohistochemical triple-staining: combination of Fos labeling with dianobenzidine-nickel and neuropeptides labeled with Alexa488 and Alexa555 fluorescent dyes. *Endocr Regul* 2012, 46, (4), 217-23.

41. Paxinos, G.; Watson, C., *Paxino’s and Watson’s The rat brain in stereotaxic coordinates*. Seventh edition. ed.; Elsevier/AP, Academic Press is an imprint of Elsevier: Amsterdam; Boston, 2014; p 1 volume (unpaged).

42. Csatlosova, K.; Bogi, E.; Durisova, B.; Grinchii, D.; Paliokha, R.; Moravcikova, L.; Lacinova, L.; Jezova, D.; Dremencov, E., Maternal immune activation in rats attenuates the excitability of monoamine-secreting neurons in adult offspring in a sex-specific way. *Eur Neuropsychopharmacol* 2020.

43. Dremencov, E.; Csatlosova, K.; Durisova, B.; Lapinova, L.; Lacinova, L.; Jezova, D., Effect of physical exercise and acute escitalopram on the excitability of brain monoamine neurons: in vivo electrophysiological study in rats. *Int J Neuropsychopharmacol* 2017.

44. Grinchii, D.; Paliokha, R.; Tseliikman, V.; Dremencov, E., Inhibition of cytochrome P450 by proadifen diminishes the excitability of brain serotonin neurons in rats. *General Physiology and Biophysics* 2018, 37, (6), 711-713.

45. Vandermaelen, C. P.; Aghajanian, G. K., Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices. *Brain Res* 1983, 289, (1-2), 109-19.